REGENXBIO Reports First Quarter 2024 Update On Duchenne muscular dystrophy Program

REGENXBIO provided a clinical and regulatory update on their Duchenne muscular dystrophy program highlighting progress in dose selection for their upcoming pivotal study which is expected to begin dosing patients in late Q3 2024 to early Q4 2024.

In new data announced today from the second patient (aged 8.1 years) at dose level 2 from the Phase I/2 AFFINITY DUCHENNE trial, RGX-202 microdystrophin expression was measured to be 20.9% compared to control at three months and this was this accompanied with a reduction in serum creatinine kinase levels of 90% at 10 weeks. RGX-202 continues to be well tolerated in all patients with no serious adverse events, and they expect to enroll up to a total of seven patients at the pivotal dose through early Q3 2024.

Further details on the corporate update can be found HERE.